# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001571049-16-013792
Filing Date
2016-04-11
Accepted
2016-04-11 17:23:56
Documents
5
Period of Report
2016-05-26
Effectiveness Date
2016-04-11

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | t1600915-def14a.htm | DEF 14A | 527927
2 | GRAPHIC | t1600915_pc1.jpg | GRAPHIC | 940819
3 | GRAPHIC | t1600915_pc2.jpg | GRAPHIC | 781539
4 | GRAPHIC | t1600915_pc3.jpg | GRAPHIC | 777613
5 | GRAPHIC | t1600915_pc4.jpg | GRAPHIC | 661458
| Complete submission text file | 0001571049-16-013792.txt |  | 4875549

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 161565871
SIC: 2834 Pharmaceutical Preparations